PharmaCyte Biotech, Inc.
PharmaCyte Biotech, Inc. (PMCB) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · PMCB · as of Sep 30, 2025
Ownership Breakdown
22
Institutional Holders
▲ 1 vs Q2
$419,852
Total Inst. Value
▼ $212,225 vs Q2
6.80M
Shares Outstanding
freeFloat 81.06%
433,089
13F Shares Held
▼ 143,430 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
PMCB largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
GEODE CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 126.6K | 1.86% | 1.86% | $122.77M | Nov 12, 2025 | — held |
EQUITEC PROPRIETARY MARKETS, LLC biological products, (no diagnostic substances) | 82.7K | 1.22% | 1.22% | $80.21M | Nov 26, 2025 | — held |
RENAISSANCE TECHNOLOGIES LLC biological products, (no diagnostic substances) | 80.0K | 1.18% | 1.18% | $77.57M | Nov 13, 2025 | ▲ 30.2K |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 74.9K | 1.10% | 1.10% | $72.67M | Nov 7, 2025 | ▼ 119.5K |
SCHONFELD STRATEGIC ADVISORS LLC biological products, (no diagnostic substances) | 26.2K | 38.55% | 38.55% | $25.40M | Nov 14, 2025 | — held |
NORTHERN TRUST CORP biological products, (no diagnostic substances) | 19.2K | 28.26% | 28.26% | $18.62M | Nov 14, 2025 | — held |
CITADEL ADVISORS LLC biological products, (no diagnostic substances) | 14.5K | 21.38% | 21.38% | $14.09M | Nov 14, 2025 | NEW |
CITADEL ADVISORS LLC biological products, (no diagnostic substances) | 10.6K | 15.60% | 15.60% | $10.28M | Nov 14, 2025 | ▲ 10.6K |
TOWER RESEARCH CAPITAL LLC (TRC) biological products, (no diagnostic substances) | 5.6K | 8.17% | 8.17% | $5.38M | Nov 14, 2025 | ▲ 2.8K |
UBS GROUP AG biological products, (no diagnostic substances) | 1.3K | 1.95% | 1.95% | $1.28M | Nov 13, 2025 | ▼ 21.3K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
5
Increased
+43.6K shares5
New Positions
first time holders4
Decreased
−140.8K shares6
Sold Out
fully exitedNet shares change (top 50)
97.2K
+43.6K / −140.8K
Net new holders
+0
5 new / 6 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
PMCB insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
10
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
WEINSTEIN ROBERT director | Mar 31, 2026 | Award | 119,170 | $0.67 | $79.8K | 119.2K | Form 4 ↗ |
WALKER WAYNE REMELL director | Mar 31, 2026 | Award | 119,170 | $0.67 | $79.8K | 119.2K | Form 4 ↗ |
SCHECHTER JONATHAN director | Mar 31, 2026 | Award | 119,170 | $0.67 | $79.8K | 119.2K | Form 4 ↗ |
Abecassis Michael M director | Mar 31, 2026 | Award | 119,170 | $0.67 | $79.8K | 119.2K | Form 4 ↗ |
Silverman Joshua CEO and President | Jan 7, 2026 | Purchase | 40,000 | $0.83 | $33.3K | 416.3K | Form 4 ↗ |
Silverman Joshua CEO and President | Jan 6, 2026 | Purchase | 30,000 | $0.79 | $23.7K | 376.3K | Form 4 ↗ |
Silverman Joshua CEO and President | Jan 5, 2026 | Purchase | 30,000 | $0.78 | $23.5K | 346.3K | Form 4 ↗ |
SCHECHTER JONATHAN director | Jan 7, 2026 | Purchase | 20,000 | $0.84 | $16.9K | 192.5K | Form 4 ↗ |
SCHECHTER JONATHAN director | Jan 6, 2026 | Purchase | 20,000 | $0.79 | $15.8K | 172.5K | Form 4 ↗ |
SCHECHTER JONATHAN director | Jan 5, 2026 | Purchase | 20,000 | $0.78 | $15.6K | 152.5K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
PharmaCyte Biotech, Inc. (PMCB) is primarily owned by institutional investors, who hold approximately 6.4% of total shares outstanding. Company insiders own approximately 18.94%, while retail and public investors account for the remaining 74.69%.
The largest institutional shareholder of PharmaCyte Biotech, Inc. is GEODE CAPITAL MANAGEMENT, LLC, holding approximately 126,603 shares — equal to 1.86% of outstanding shares — as of September 30, 2025.
A total of 22 institutional investors currently hold PMCB stock, with a combined institutional value of approximately $419,852 as of the most recent 13F filing period.
Frequently asked questions
PMCB ownershipPharmaCyte Biotech, Inc. (PMCB) is primarily owned by institutional investors, who hold approximately 6.4% of shares. The largest shareholder is GEODE CAPITAL MANAGEMENT, LLC with a 1.86% stake. Company insiders hold 18.94%. Data sourced from SEC Form 13F as of September 30, 2025.